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MicroRNAs 146a/b-5 and 425-3p and 24-3p are
markers of antidepressant response and regulate
MAPK/Wnt-system genes
Juan Pablo Lopez1, Laura M. Fiori1, Cristiana Cruceanu1, Rixing Lin1, Benoit Labonte2, Hannah M. Cates2,
Elizabeth A. Heller2, Vincent Vialou2, Stacy M. Ku2, Christophe Gerald2, Ming-Hu Han2, Jane Foster3,
Benicio N. Frey4, Claudio N. Soares5,6, Daniel J. Mu¨ller3,7, Faranak Farzan3,7,8, Francesco Leri9,
Glenda M. MacQueen10, Harriet Feilotter11, Kathrin Tyryshkin11, Kenneth R. Evans11,12, Peter Giacobbe3,
Pierre Blier13, Raymond W. Lam14, Roumen Milev15, Sagar V. Parikh16, Susan Rotzinger3, Steven C. Strother17,
Cathryn M. Lewis18, Katherine J. Aitchison19,20, Gayle M. Wittenberg21, Naguib Mechawar1, Eric J. Nestler2,
Rudolf Uher18,20, Sidney H. Kennedy3 & Gustavo Turecki1
Antidepressants (ADs) are the most common treatment for major depressive disorder
(MDD). However, only B30% of patients experience adequate response after a single AD
trial, and this variability remains poorly understood. Here, we investigated microRNAs
(miRNAs) as biomarkers of AD response using small RNA-sequencing in paired samples from
MDD patients enrolled in a large, randomized placebo-controlled trial of duloxetine collected
before and 8 weeks after treatment. Our results revealed differential expression of miR-146a-
5p, miR-146b-5p, miR-425-3p and miR-24-3p according to treatment response. These results
were replicated in two independent clinical trials of MDD, a well-characterized animal model
of depression, and post-mortem human brains. Furthermore, using a combination of bioin-
formatics, mRNA studies and functional in vitro experiments, we showed signiﬁcant dysre-
gulation of genes involved in MAPK/Wnt signalling pathways. Together, our results indicate
that these miRNAs are consistent markers of treatment response and regulators of the
MAPK/Wnt systems.
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M
ajor depressive disorder (MDD) is a prevalent illness
that associates with signiﬁcantly increased mortality,
disability and secondary morbidity, and is one of the
world’s leading causes of disease burden1. Treatment of MDD
includes a variety of biopsychosocial approaches, but in medical
practice, antidepressant (AD) drugs are the most common
treatment for depressive episodes and, not surprisingly, they are
among the most prescribed medications in the world2. While they
are clearly effective, particularly for moderate-to-severe
depressive episodes, there is substantial variability in how
individuals respond to AD treatment. In spite of the many ADs
available, almost 70% of patients do not respond to a single trial
and 30–40% of patients do not present with a full response
following several trials3. The failure to respond has important
individual, economic and social consequences for both patients
and their families. Thus, there is a great need to better understand
factors associated with response to AD treatment.
Genes can be regulated through the activity of several
noncoding RNA transcripts that act as ﬁne-tuners and on–off
switches of gene expression patterns4. Among the noncoding
RNAs, microRNAs (miRNAs) have been the most extensively
studied5. Since their discovery in the early 1990s, miRNAs have
revolutionized our understanding of gene regulation and show
great potential for assisting in the elucidation of mechanisms
underlying disease pathology and treatment response6. MiRNAs
are small noncoding, single-stranded RNA transcripts that
regulate the expression of mRNAs through RNA degradation or
translational repression. There is increasing evidence suggesting a
key role for miRNAs in the regulation of essential processes of
brain functioning, as well as in the development of psychiatric
disorders and their treatments7. For instance, Baudry et al.8,9
found that miR-16 mediates AD action of ﬂuoxetine in the raphe
and locus coeruleus of mice, and follow-up work suggested that
this same miRNA displays antidepressant-like effects and
mediates adult neurogenesis in the hippocampus. Another
recent and promising ﬁnding uncovered a key role for miR-
135a in the molecular mechanisms underlying the therapeutic
actions of ADs in both depressed humans and animal models of
depression10. Dias et al.11 showed that the miRNA processing
protein, Dicer, acts in brain reward regions to promote
antidepressant-like responses in animal models. Finally, we
have recently reported that miR-1202, a primate-speciﬁc and
brain-enriched miRNA, is downregulated in the prefrontal cortex
of depressed individuals and regulates the expression of the
metabotropic glutamate receptor (GRM4)12. These encouraging
new ﬁndings underline the potential of studying miRNAs to
better understand molecular processes associated with MDD.
Here, we investigate miRNAs in relation to AD response. Using
complementary strategies, we demonstrate that levels of miR-
146a-5p, miR-146b-5p, miR-24-3p and miR-425-3p are modiﬁed
as a function of AD response and regulate genes involved in
mitogen-activated protein kinase (MAPK) and Wnt signalling
pathways.
Results
MicroRNA dysregulation after antidepressant treatment. We
performed small RNA-sequencing in blood samples from a ran-
domized placebo-controlled trial of duloxetine, a serotonin–
norepinephrine reuptake inhibitor. Blood samples were collected
before and 8 weeks after treatment (discovery cohort (DRCT);
n¼ 516 samples from 258 patients) (Fig. 1a). We compared the
expression of miRNAs before and after treatment (that is, 8-week
response to baseline). Statistical analysis, using Benjamini–
Hochberg correction for multiple testing (5% false discovery
rate (FDR)) and corrected P values ofo0.05, revealed differential
expression of 22 miRNAs after 8 weeks of duloxetine treatment
(Table 1) and 6 miRNAs after 8 weeks of placebo treatment
(Table 2). Except for one miRNA, these ﬁndings were speciﬁc to
patients who responded to treatment with no differences found in
the nonresponder groups (Fig. 1a and Supplementary Tables 1
and 2). We deﬁned response as450% decrease in Montgomery–
Åsberg Depression Rating Scale (MADRS) scores from baseline
to trial end point13–15. Remarkably, the six miRNAs that
were signiﬁcantly changed according to placebo response were
among the 22 whose expression changed according to
duloxetine response, and were altered in the same direction
(Tables 1 and 2; Fig. 1b). Thus, 16 miRNAs changed speciﬁcally
according to duloxetine treatment. One miRNA (miR-503-5p)
was signiﬁcantly changed in responders and nonresponders in
both placebo- and duloxetine-treated patients, suggesting that the
alterations in the expression of this miRNA may associate with
metabolic processes that are independent of clinical outcome.
We validated our signiﬁcant ﬁndings using a high-sensitivity
multiplex cellular miRNA assay on a standard ﬂow cytometer
(Fireﬂy BioWorks). Using a custom panel, we measured miRNA
expression before and after treatment in the same 516 samples
used for small RNA-sequencing. We validated 87% of the
miRNAs tested (Supplementary Table 3) and found a signiﬁcant
correlation of fold changes across the two technologies (r¼ 0.83,
Po0.05; Fig. 1c). Since we were interested in the underlying
molecular mechanisms involved in response to treatment, and
based on recent evidence suggesting that some of the mechanisms
involved in placebo response are also engaged during AD
treatment and could reinforce response to common AD16,17, we
next focused on the miRNAs that were differentially expressed
according to response in both the duloxetine and placebo groups.
These were miR-146a-5p, miR-146b-5p, miR-24-3p, miR-425-3p
and miR-3074-5p that were all downregulated after treatment,
and their individual expressions were strongly correlated
(Fig. 1d,e and Supplementary Table 4) suggesting a shared
mechanism of action.
Independent replication with cohort 1. To test the external
validity of our ﬁndings, we measured the expression of these ﬁve
miRNAs before and after 8 weeks of AD treatment in a fully
independent sample composed of 61 depressed patients (122
samples) who were recruited as part of the Genome-based
Therapeutic Drugs for Depression (GENDEP) study18
(replication cohort 1). Patients were treated with escitalopram,
a selective serotonin reuptake inhibitor, or nortriptyline, a
tricyclic antidepressant (Fig. 2a). In line with our ﬁndings in
the DRCT, we again found a signiﬁcant downregulation in the
expression of miR-146a-5p, miR-146b-5p, miR-24-3p and miR-
425-3p in the blood of depressed patients after treatment.
Importantly, these changes were consistent with those observed
in the discovery cohort (Fig. 2b and Supplementary Table 5).
Although we also saw a decrease in the expression of miR-3074-
5p, this effect was not statistically signiﬁcant, and thus we did not
include this miRNA in further analyses. Consistent with our
initial ﬁndings, the downregulation of the validated miRNAs was
only observed among responders to treatment, as we found no
changes in the expression of these miRNAs in the nonresponder
group. These ﬁndings support a relationship between treatment
response and miR-146a-5p, miR-146b-5p, miR-24-3p and miR-
425-3p.
Independent replication with cohort 2. We measured the
expression of miR-146a-5p, miR-146b-5p, miR-24-3p and miR-
425-3p before and after 8 weeks of AD treatment in a second
independent sample composed of 316 additional blood samples
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Figure 1 | MicroRNA changes after 8 weeks of AD treatment. (a) Experimental design. Discovery cohort (DRCT), baseline (T0), 8 weeks of treatment
(T8), responders (RES) and nonresponders (NRES), *Number of signiﬁcant miRNAs. (b) Venn diagram showing speciﬁc and commonly dysregulated
miRNAs in duloxetine and placebo responders. (c) Correlation between miRNAs measured by small RNA-sequencing and a high-sensitivity multiplex
cellular miRNA assay on a standard ﬂow cytometer (Fireﬂy BioWorks). (d) Small RNA Sequencing expression (number of reads per million, Log2) of miR-
146a-5p, miR-146b-5p, miR-24-3p, miR-425-3p and miR-3074-5p after 8 weeks in MDD patients who responded to duloxetine treatment. ***FDR
corrected Po0.001. (e) Scatterplots of Pearson’s correlations between differentially expressed miRNAs in blood samples from the discovery cohort.
***Po0.001.
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from 158 patients treated with the antidepressant escitalopram
(selective serotonin reuptake inhibitor) for 8 weeks. All patients
from cohort 2 (RPCT2) were recruited as part of the Canadian
Biomarker Integration Network in Depression (CAN-BIND)
study19. (Fig. 2c). In line with all our previous ﬁndings, we found
consistent results, both in signiﬁcance and direction, for three out
of the four miRNAs tested (Fig. 2d and Supplementary Table 6).
There was a downregulation of miR-146a-5p, miR-146b-5p and
miR-24-3p after antidepressant treatment. More importantly,
these effects were only observed among responders to
escitalopram treatment, as we found no changes in the
expression of these miRNAs in the nonresponder group. We
found no signiﬁcant differences in the levels of miR-425-3p in our
second replication cohort (Fig. 2d and Supplementary Table 6).
These ﬁndings support a relationship between these miRNAs and
treatment response in humans.
Ruling out effects of differential blood cellular composition. To
control for possible biases arising from differential blood sample
cellular composition between groups, we used haematology data
collected in the discovery sample during the randomized
placebo-controlled trial. We found no signiﬁcant differences
between groups or categories (before and after treatment,
between responders and nonresponders, and between dulox-
etine- and placebo-treated individuals) in the levels or
proportions of any of the cell types investigated in the blood
samples from either duloxetine-treated patients or placebo
controls (Supplementary Tables 7 and 8). More importantly, we
measured the levels of the validated and replicated miRNAs in
cell-free plasma samples obtained from these subjects, and
observed results that were similar to those observed with the
whole blood samples, both in signiﬁcance and direction
(Supplementary Fig. 1).
Dysregulation of miRNAs after antidepressant treatment in mice.
We next investigated the relevance of our results in a well-estab-
lished animal model of depression20. We tested mice exposed to the
chronic social defeat stress (CSDS) paradigm followed by the social
interaction and sucrose preference tests to distinguish between
susceptible animals, which show deﬁcits in these behaviours, and
resilient animals, which do not20. Susceptible mice were then treated
with the antidepressant imipramine (tricyclic antidepressant) or
saline control for 14 days followed by a repeat of the social
interaction and sucrose preference tests. Mice that showed
improvement in depression-like symptoms in these behavioural
assays were classiﬁed as responders, while those that showed no
improvements were deemed as nonresponders (Fig. 3a). We
measured the expression of miR-146a-5p, miR-146b-5p, miR-24-
3p and miR-425-3p in peripheral blood samples of mice before and
after treatment with imipramine or saline control, using a
NanoString, a probe-based miRNA expression assay. We found a
signiﬁcant downregulation of miR-146b-5p, miR-24-3p and miR-
425. In addition, we found a decrease in the expression of miR-
146a-5p, but these ﬁndings did not reach statistical signiﬁcance
(P¼ 0.09; Fig. 3b). Consistent with the data in humans, these
changes were selective for the responder group, as no differences
were detected in the nonresponders or saline control groups
(Table 3). These results reinforce the relationship between these
miRNAs and treatment response.
Dysregulation of miRNAs in the vPFC of depressed individuals.
To explore the relationship between the peripheral changes of
miR-146a-5p, miR-146b-5p, miR-24-3p and miR-425-3p, and
their expression in the brain, we used quantitative real-time
PCR to assess the levels of these miRNAs in the ventrolateral
prefrontal cortex (vPFC) of depressed humans who died by
suicide (n¼ 32) and psychiatrically healthy controls (n¼ 20).
We found a signiﬁcant difference in the expression of each of
these miRNAs compared with controls (Fig. 3c and Table 4).
Whereas the peripheral samples from AD treatment responders
showed decreased expression of the candidate miRNAs, these
miRNAs were all upregulated in depressed brain tissue relative
to healthy controls (Fig. 3c and Table 4). Additionally, their
expression was strongly correlated in brain tissue, again
suggesting a common mechanism of action (Supplementary
Fig. 2 and Supplementary Table 9).
miRNA target prediction and pathway analysis. Gene targets of
miR-146a-5p, miR-146b-5p, miR-24-3p and miR-425-3p were
identiﬁed using seven miRNA target prediction databases. We
opted to consider only targets that were commonly predicted by
at least 5 out of the 7 prediction databases, and obtained a list of
5,806 putative target genes (Fig. 4a). As the changes of these 4
miRNAs were positively correlated, we hypothesized that they
had common pathways of regulation, and thus narrowed our list
of targets by considering only genes that were commonly pre-
dicted targets for at least 3 of the miRNAs, producing a list of 895
genes. We then used the Database for Annotation, Visualization
and Integrated Discovery (DAVID) v6.7 (ref. 21) to identify
Table 1 | Duloxetine responders.
hsa-miRNA FC (T0 versus T8) Adjusted P value
miR-425-3p 0.46 2.639E08
miR-24-3p 0.70 6.813E06
miR-503-5p 0.45 6.987E06
miR-146a-5p 0.60 3.748E05
miR-215-5p 1.50 8.744E05
miR-3074-5p 0.76 1.616E04
miR-1180-3p 0.75 2.487E04
miR-425-5p 0.86 0.001
miR-324-5p 0.78 0.001
miR-146b-5p 0.66 0.001
miR-6750-3p 1.27 0.005
miR-6511a-3p 1.21 0.007
miR-361-5p 0.84 0.009
miR-3173-5p 1.30 0.023
miR-2110 0.81 0.026
miR-3605-3p 1.17 0.032
miR-6881-3p 1.27 0.032
miR-30e-5p 1.19 0.035
miR-423-3p 1.12 0.035
miR-361-3p 1.10 0.040
miR-3184-5p 1.12 0.050
hsa-miR-636 1.14 0.050
FC, fold change; hsa, Homo sapiens.
Fold change is reported in the centre column and miRNAs are ranked according to adjusted P
values (Benjamini–Hochberg correction for multiple testing).
Table 2 | Placebo responders.
hsa-miRNA FC (T0 versus T8) Adjusted P value
miR-146a-5p 0.49 1.860E05
miR-425-3p 0.50 1.415E04
miR-24-3p 0.76 3.255E04
miR-146b-5p 0.79 0.004
miR-503-5p 0.48 0.007
miR-3074-5p 0.73 0.007
FC, fold change; hsa, Homo sapiens.
Fold change is reported in the centre column and miRNAs are ranked according to adjusted
P values (Benjamini–Hochberg correction for multiple testing).
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biological pathways that were potentially regulated by these
miRNAs. Functional Annotation Clustering analysis revealed an
enrichment of ﬁve signalling pathways. The MAPK, Wnt,
calcium, endocytosis and adherens junction signalling pathways
were signiﬁcantly enriched after Benjamini–Hochberg correction
for multiple testing (Po0.05; Fig. 4a,b). To validate our miRNA
target prediction and pathway analysis, we performed a second,
independent in silico analysis using DIANA: miRPath22.
Consistent with our ﬁrst in silico analysis, we found
a signiﬁcant enrichment of the MAPK, Wnt, calcium,
endocytosis and adherens junction signalling pathways after
FDR correction for multiple testing (Po0.05). Interestingly, the
MAPK and Wnt signalling pathways are modulated by stress and
have been previously implicated in MDD and treatment response
in humans and animal models11,23–25.
MiRNA regulation of MAPK/Wnt signalling after treatment.
To explore the relationship between the downregulated miRNAs
and predicted signalling pathways, we cross-referenced the
expression of miR-146a-5p, miR-146b-5p, miR-24-3p and miR-
425-3p with the genes identiﬁed through our computational
analysis. Given the previous evidence suggesting changes in the
MAPK and Wnt signalling pathways in depression, we focused
only on these two pathways. First, we used mRNA microarray
expression data obtained from blood of the DRTC samples
(n¼ 460 samples from 230 patients). Interestingly, we found that
most of the predicted target genes involved in MAPK and Wnt
signalling pathways were signiﬁcantly correlated with the
expression of one or more of the miRNAs tested (89%)
(Supplementary Table 10). However, this effect was signiﬁcantly
stronger in patients who responded to treatment (Fig. 4c and
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Supplementary Table 11). In addition, 69% of these genes were
signiﬁcantly dysregulated following duloxetine treatment
(Supplementary Fig. 3). We then performed a similar analysis
using complementary miRNA and gene expression data obtained
from our replication cohort (n¼ 102 samples from 51 patients).
We consistently found a signiﬁcant correlation between predicted
genes involved in MAPK and Wnt signalling pathways and the
expression of the downregulated miRNAs in depressed patients
who responded to treatment (71%) (Supplementary Table 12).
Once again, the effect was stronger in the responder group as
compared with the nonresponder group (Fig. 4d). To verify that
the correlation between these miRNAs and theMAPK/Wnt genes
identiﬁed through our in silico analysis was not a random ﬁnding,
we performed a permutation analysis to test correlations between
miR-146a-5p, miR-146b-5p, miR-24-3p, miR-425-3p and 50
random genes. We found that the average percentage of sig-
niﬁcant correlations with 50 random genes after 100 permuta-
tions was 12% for all miRNAs tested, suggesting that the results
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found in our discovery (89%) and replication (71%) cohorts were
signiﬁcantly above chance levels. Together, these results support
a relationship between these miRNAs and the MAPK/Wnt sig-
nalling pathways after antidepressant treatment.
MicroRNA dysregulation of MAPK/Wnt signalling in vitro. To
conﬁrm that antidepressants have an effect on the expression of
miR-146a-5p, miR-146b-5p, miR-24-3p and miR-425-3p, we
treated human neural progenitor cells (NPCs) with duloxetine,
the same antidepressant that was used in the DRTC, as well as a
no-drug control. NPCs display a serotonergic phenotype and
express endogenous levels of the serotonin transporter (SERT) and
several other serotonin receptors12. Following chronic duloxetine
treatment for 2 weeks, we found a signiﬁcant downregulation of
miR-146a-5p, miR-146b-5p, miR-24-3p and miR-425-3p
(Fig. 5a), with no differences in the expression of the
endogenous control RNU6B after treatment or changes in these
miRNAs after 2 weeks in untreated cells. In addition, we tested
the expression of the predicted target genes involved in MAPK
and Wnt signalling pathways that were correlated in our
discovery and replication cohorts. We found a dysregulation in
the expression of most (92%) MAPK/Wnt genes tested after
chronic duloxetine treatment, but found no signiﬁcant differences
in the expression of the endogenous controls b-Actin and
GAPDH. Most importantly, and consistent with our miRNA
ﬁndings, we found an upregulation of these genes after treatment
as compared with controls (Fig. 5b). These results support an
interaction between these four miRNAs, the MAPK/Wnt
signalling pathways and antidepressant treatment.
Finally, to experimentally conﬁrm the interaction between
miR-146a-5p, miR-146b-5p, miR-24-3p, miR-425-3p and genes
of the MAPK/Wnt signalling pathways, we performed functional
experiments using miRNA mimics on human embryonic kidney
cells (HEK293). The HEK293 cells showed relatively high levels of
all genes tested, but low levels of the miRNAs tested and thus
provided a good model for our functional assays. We examined
whether overexpression of any of these miRNAs affects the
expression of MAPK/Wnt genes in vitro. Cells were transfected
for 24 h with a miRNA mimic for each of the individual miRNAs
(miR-146a-5p, miR-146b-5p, miR-24-3p and miR-425-3p), a
miRNA-mimic scramble control or a mock vehicle, and results
were compared with untreated cells. A one-way analysis of
variance showed that all of the MAPK/Wnt genes tested were
downregulated by at least one of the miRNA mimics transfected
(Fig. 5c,d). Seven of the tested genes were downregulated by each
of the four miRNA mimics. Thirteen genes were downregulated
by three of the four miRNA mimics. Two genes were down-
regulated by two of the four miRNA mimics and one gene was
only downregulated by one of the four miRNA mimics (Fig. 5c,d
and Supplementary Table 13). We found no effects on any of
these genes after treatment with the scramble or vehicle controls.
In addition, we did not ﬁnd any changes in the expression of
GAPDH or b-Actin after transfection of the mimics, scramble or
vehicle controls. These results conﬁrm an interaction between
miR-146a-5p, miR-146b-5p, miR-24-3p, miR-425-3p and the
MAPK/Wnt signalling pathways.
Discussion
These miRNAs are transcribed from different genomic loci: chr5
(miR-146a-5p), chr10 (miR-146b-5p), chr9/chr19 (miR-24-3p)
and chr3 (miR-425-3p). They are ubiquitously expressed, highly
correlated in blood and brain tissue, and also expressed in other
human biological ﬂuids (Supplementary Figs 4 and 5). Based on
our results, we propose a potential mechanism of action for these
miRNAs through regulation of the MAPK and Wnt signalling
pathways. Interestingly, inhibition of these pathways has been
shown to lead to a depressive phenotype, while activation has
been strongly associated with a decrease in depressive symptoms
and improved antidepressant response in both central and
peripheral systems26–30. Here, we showed that miR-146a-5p,
miR-146b-5p, miR-24-3p and miR-425-3p regulate the
expression of 430 genes involved in MAPK and Wnt
signalling. Remarkably, most of these genes have been
previously associated with MDD or antidepressant activity
(Supplementary Table 14). In addition, we found
a dysregulation of key genes involved in neurotrophic factor
signalling that is directly coupled to MAPK activity. The
tropomyosin receptor kinase B (NTRK2) is the preferred
receptor of the brain-derived neurotrophic factor (BDNF) and
a key player in the neurotropic hypothesis of depression31,32,
while the ﬁbroblast growth factor (FGF2) is a vital growth factor
recently shown to promote neuronal plasticity, proliferation,
survival, differentiation and synaptic function33. Both of these
genes have been shown to regulate neurogenic mechanisms and
antidepressant response23,26. Other genes involved in calcium
signalling, endocytosis and adherens junctions are also potentially
regulated by these miRNAs.
In summary, we report a consistent dysregulation of
miRNAs in peripheral blood samples from depressed patients
after antidepressant treatment. Our ﬁndings indicate that
miR-146a-5p, miR-146b-5p, miR-24-3p and miR-425-3p are
consistent blood markers of antidepressant response and
regulators of psychiatrically relevant signalling pathways. More
importantly, we showed consistent changes in the expression of
these miRNAs in patients who respond to treatment with
different classes of ADs, as well as in stressed mice that respond
to AD, suggesting their involvement in a common mechanism
of action. These results have important implications for the
elucidation of biological mechanisms involved in clinically
relevant antidepressant effects and suggest that these miRNAs
could potentially be used as correlates or state biomarkers of
treatment response. Ultimately, our results underline the
potential of studying miRNAs to better understand molecular
processes associated with MDD and provide valuable
Table 3 | Animal model of MDD.
mmu-
miRNA
Controls
saline
treated
Susceptible
saline
treated
Susceptible
imipramine
(RES)
Susceptible
imipramine
(NRES)
miR-425 0.956 0.493 0.007 0.618
miR-146b 0.653 0.557 0.041 0.304
miR-24 0.823 0.592 0.047 0.240
miR-146a 0.939 0.392 0.090 0.213
NRES, nonresponders; RES, responders.
P values across treatment groups.
Table 4 | MiRNA expression in vPFC of post-mortem brains
of subjects with MDD and controls.
hsa-miRNA FC P value
miR-425-3p 1.31 0.005
miR-24-3p 1.26 0.037
miR-146a-5p 1.28 0.031
miR-146b-5p 1.29 0.028
FC, fold change; hsa, Homo sapiens.
Quantitative real-time (qRT-PCR) expression data in vPFC of post-mortem brains of subjects
with MDD and controls.
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information for the development of diagnostic tools, precau-
tionary approaches and successful pharmacological interven-
tions for MDD.
Methods
Human samples. A total of 1,006 human samples were included in the present
study, and include (1) discovery cohort (DRCT; n¼ 516 samples from 258
patients) obtained in collaboration with the CAN-BIND and Lundbeck A/S
sponsored clinical trials; (2) replication cohort 1 (RPCT1, n¼ 122 samples from
61 patients) obtained in collaboration with the GENDEP consortium; (3) repli-
cation cohort 2 (RPCT2, n¼ 316 samples from 158 patients) obtained in colla-
boration with CAN-BIND; and (4) post-mortem, prefrontal cortex brain tissue
(n¼ 52) that was obtained in collaboration with the Quebec Coroner’s Ofﬁce and
the Douglas-Bell Canada Brain Bank (Douglas Mental Health University Institute,
Montreal, Canada). Ethics approval for this study was obtained from the institu-
tional review board of the Douglas Mental Health University Institute, and written
informed consent was obtained from patients or family members, as appropriate.
Our DRCT consisted of 258 well-characterized individuals (females n¼ 178;
males¼ 80) diagnosed with MDD in a current major depressive episode (MDE)
who were enrolled in a clinical trial and received treatment with either duloxetine
or placebo. Duloxetine is a serotonin–norepinephrine reuptake inhibitor. For each
patient, peripheral blood samples were collected at baseline and after treatment.
Participants, aged 19–74 years, were recruited based on a primary diagnosis of
MDD and MDE lasting at least 3 months, with a severity score on the MADRS at
baseline of Z22. Participants resistant to at least two previous AD treatments or
who had received electroconvulsive therapy in the 6 weeks before study beginning
were excluded. Other exclusion criteria were: MDE in bipolar disorder, presence of
psychotic features and recent substance use disorder. Eligible participants were
equally randomized to double-blind treatment with either duloxetine (60mg) or
placebo. All participants were assessed prospectively for 8 weeks, including
measures of depressive severity and potential related adverse events. To quantify
treatment response, we calculated percentage change of MADRS scores (from
baseline to after treatment). We used percentage change to correct for the potential
effects of differential baseline scores. Additionally, we classiﬁed participants as
responder/nonresponder based on 450% decrease in MADRS scores from
baseline. This project was approved by ethics boards of participating centres, and
all participants provided written informed consent. Clinical trials are registered at
www.ClinicalTrials.gov (11984A NCT00635219; 11918A NCT00599911; 13267A
NCT01140906)
Our RPCT1 consisted of 61 well-characterized individuals (females n¼ 40;
males¼ 21) diagnosed with MDD and enrolled in the GENDEP project. Adult
patients with major depression of at least moderate severity according to ICD-10
(International Statistical Classiﬁcation of Diseases and Related Health Problems,
10th revision) or DSM-IV (Diagnostic and Statistical Manual of Mental Disorders,
4th Edition) criteria were recruited at ﬁve European centres. Patients were
aged 21–70 years and of Caucasian European parentage. Exclusion criteria were
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Figure 4 | Target prediction analysis and miRNA regulation of MAPK and Wnt signalling after antidepressant treatment. (a) Target prediction analysis
using seven miRNA target prediction sites (mTPS): miRWalk 2.0, miRDB, miRanda, RNA22 v2, RNAHybrid, TargetScan and DIANA Tools. Biological
pathway analysis using the Database for Annotation, Visualization and Integrated Discovery (DAVID) v6.7. (b) Circo graph shows the relationship between
miR-146a-5p, miR-146b-5p, miR-24-3p and miR-425-3p with 36 predicted MAPK and Wnt genes identiﬁed through our in silico analysis. Each ribbon
connects a miRNA with a predicted target gene. (c,d) Correlation analysis between miR-146a-5p, miR-146b-5p, miR-24-3p, miR-425-3p and MAPK/Wnt
genes in the discovery and replication cohorts. Heatmap represents P values of Pearson’s correlations.
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personal and family history of schizophrenia or bipolar disorder, or current
substance dependence. Eligible participants were allocated to treatment with either
escitalopram or nortriptyline that represent different antidepressant classes and
mechanisms of action. Patients with contraindications for one drug were offered
the other. Severity of depression was assessed at baseline and after treatment by
three established rating scales. The GENDEP project was approved by ethics boards
of participating centres, and all participants provided written informed consent.
The GENDEP trial is registered at EudraCT (no. 2004-001723-38) and ISRCTN
(no. 03693000).
RPCT2 consisted of 158 well-characterized individuals (females n¼ 98;
males¼ 60) diagnosed with MDD and enrolled in the CAN-BIND project19. Adult
patients with major depression of at least moderate severity according to DSM-IV-
Text Revision (TR) criteria were recruited at six Canadian clinical centres. Patients
were aged 18–60 years. Exclusion criteria were personal and family history of
schizophrenia or bipolar disorder, or current substance dependence. Eligible
participants were allocated to treatment with escitalopram (10–20mg per day)
for 8 weeks. Severity of depression was assessed at baseline and after treatment
by the MADRS. The CAN-BIND project was approved by ethics boards of
participating centres, and all participants provided written informed consent. The
CAN-BIND trial is registered at ClinicalTrials.gov identiﬁer NCT01655706.
Registered 27 July 2012.
Human post-mortem prefrontal cortex brain tissue was obtained in
collaboration with the Quebec Coroner’s Ofﬁce and the Douglas-Bell Canada
Brain Bank (Douglas Mental Health University Institute, Montreal, Quebec,
Canada). A total of 52 brain samples were included in the present study. Thirty
two depressed suicide completers and 20 non-suicide controls were randomly
selected for miRNA analysis. All individuals were of French–Canadian origin, a
homogeneous population with a well-documented founder effect, and were
matched for refrigeration delay, age and pH. Refrigeration delay refers to the
difference between the estimated time of death (determined by the pathologist
through external body examination details) and the time at which the brain was
refrigerated. Psychological autopsies were performed post mortem on both cases
and controls by a panel of psychiatrists, and diagnoses were assigned based on
DSM-IV criteria. The control group had no history of suicidal behaviour or
major mood or psychotic disorders.
Peripheral blood samples were collected in PAXgene blood RNA tubes
(PreAnalytix). PAXgene tubes were frozen using a sequential freezing process:
tubes were stored at room temperature for 3 h, transferred to 4 C overnight,
followed by 6–8 h at  20 C and then ﬁnal storage at  80 C. Total RNA
(including the miRNA fraction) was isolated from whole blood using the PAXgene
Blood miRNA Kit (Qiagen, Canada) according to the manufacturer’s instructions.
Brain tissues were processed and dissected at 4 C, then snap-frozen in liquid
nitrogen before storage at  80 C. Total RNA was isolated from 40mg of frozen
PFC tissue using the miRNeasy Mini Kit protocol in combination with the RNeasy
MinElute Cleanup Kit (Qiagen, Canada), with no modiﬁcations. All samples were
treated with DNase digestion during RNA puriﬁcation using the RNase-Free
DNase kit (Qiagen). RNA and miRNA yield and quality were determined using the
Nanodrop 1000 (Thermo Scientiﬁc, USA) and Agilent 2100 Bioanalyzer (Agilent
Technologies, USA). The average RNA Integrity Number (RIN) value for all our
samples by group were as follows: discovery cohort RIN: 8.6, replication cohort 1
RIN: 8.3, replication cohort 2 RIN: 8.2, and post-mortem brain samples RIN: 6.7.
All libraries were prepared using the Illumina TruSeq Small RNA protocol
following the manufacturer’s instructions with 12 cycles of PCR ampliﬁcation after
ligation of the 30 and 50 adapters, as described elsewhere5. Libraries were puriﬁed
using biotinylated magnetic AMPure beads that allow for selection of speciﬁed
complementary DNA (cDNA) products bound to streptavidin. A total of 50 ml of
ampliﬁed cDNA were mixed and puriﬁed twice with AMPure XP beads in a 1.8:1
ratio (beads/sample). This ratio allows for optimal selection of all products higher
than 100 nucleotides. Library qualities were assessed using an Agilent 2100
Bioanalyzer High Sensitivity DNA chip, as well as quantitative real-time PCR with
the KAPA library quantiﬁcation kit (Kapa Biosystems, USA).
Samples were sequenced at the McGill University and Genome Quebec
Innovation Centre (Montreal, Canada) using the HiSeq2500 Illumina sequencer
with 50-nucleotide single-end reads. We obtained an average number of 12.1
million raw reads, with an average quality value of 37 in all libraries produced. All
sequencing data were processed using CASAVA 1.8þ (ref. 34) and extracted from
FASTQ ﬁles. The Fastx_toolkit was used to trim the Illumina adapter sequences.
Additional ﬁltering based on deﬁned cutoffs was applied to obtain high-quality
data. These ﬁlters included: (1) Phred quality (Q) mean scores higher than 30,
(2) reads between 15 and 40 nucleotides in length, (3) adapter detection based on
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perfect 10-nucleotide match and (4) removal of reads without detected adapter.
Additionally, we used Bowtie35 to align reads to the human genome (GRCh37)36
and ncPRO-seq37 in combination with miRBase (V20) to match them to known
miRNA sequences38,39. We used a detection threshold of 10 counts per miRNA
(present at least in 80% of libraries tested). A total of 281 miRNAs survived our
criteria and were included in the analysis. All small RNA-sequencing data were
normalized with the Bioconductor – DESeq2 package using the variance-stabilizing
transformation method40. To identify signiﬁcant microRNAs based on differential
expression changes across time, we used signiﬁcance analysis of microarrays
method, adapted for small RNA-sequencing data (SAMSeq)41. SAMSeq was
implemented using a two-class paired model that accounts for changes not only
between groups, but also within subjects as there is a one-to-one pairing between
subjects across time. We used the Benjamini–Hochberg FDR correction for
multiple testing set at 5% that corrects for the proportion of miRNAs likely to have
been identiﬁed by chance as being signiﬁcant (adjusted P valueso0.05). We also
tested for potential confounding effects of age, gender, race and RIN but found no
signiﬁcant differences across groups or time.
Small RNA-sequencing results were validated with a custom miRNA panel
using circulatory miRNA assays by Fireﬂy BioWorks. Brieﬂy, RNA samples were
hybridized to miRNA-speciﬁc probes coated on FirePlex hydrogel beads.
A universal biotinylated adapter was then ligated onto the captured miRNAs and
labelled with a ﬂuorescent reporter. The level of ﬂuorescence for a given miRNA
(particle) was detected using a Guava easyCyte 8HT ﬂow cytometer. Additionally,
miR-19b-3p, Let-7i-5p and Let-7b-5p were included as endogenous controls, as
they demonstrated the least variation across all samples in our sequencing results.
Raw data were processed using FireCode software (Fireﬂy BioWorks), and
normalized to the geometric mean of the endogenous controls. We used a two-class
paired signiﬁcant analysis of microarray analysis to determine differential gene
expression before and after treatment. Po0.05 was considered statistically signiﬁcant.
Frozen plasma was thawed at room temperature, and 625 ml of each sample was
used for total RNA extraction using the mirVana Isolation kit (ThermoFisher),
following the manufacturer’s instructions. Libraries were prepared using the Ion PI
Template OT2 200 kit Version 3 and sequenced on an Ion Proton System
(ThermoFisher). FASTQ ﬁles were downloaded from Ion Suite software and
aligned using miRBase (V20) and the hg19 genome build.
Gene targets of miR-146a-5p, miR-146b-5p, miR-24–3p and miR-425-3p
were identiﬁed using seven miRNA target prediction databases: miRWalk 2.0,
miRDB, miRanda, RNA22 v2, RNAHybrid, TargetScan and DIANA Tools42–48.
We then used DAVID v6.7 to identify potential biological pathways regulated by
these miRNAs. To validate our miRNA target prediction and pathway analysis,
we performed a second, independent, in silico analysis for miR-146a-5p, miR-
146b-5p, miR-24-3p and miR-425-3p using DIANA: miRPath. This program
allows identiﬁcation of common miRNA targets provided by the DIANA-
microT-CDS algorithm derived from DIANA-TarBase v6.0. In addition,
miRPath can perform a pathway analysis based on various levels of miRNA
interactions.
For genome-wide expression analysis in peripheral blood samples, we used the
Human HT-12 v4 Expression Bead Chip (Illumina). Background adjustment using
variance-stabilizing transformation correction and quantile normalization was
performed using the FlexArray package implemented in R (version 1.6.3). Probes
with 470% absent points among all samples were removed from downstream
analysis. A total ofB15,000 probes were included in the ﬁnal analysis. Microarray
data were analysed using a two-class paired signiﬁcant analysis of microarray, as
well as Pearson’s correlations to determine differential gene expression before and
after treatment using or correlations between miRNAs and target genes,
respectively. All analyses were performed using MultiExperiment Viewer 4 (MeV4,
TM4 software suite). Po0.05 was considered statistically signiﬁcant.
For microRNA quantiﬁcation, total RNA samples were reverse transcribed
and quantiﬁed using TaqMan RT-PCR microRNA assays (Applied Biosystems)
according to the manufacturer’s instructions. Real-time PCR reactions were run
in triplicate using the ABI 7900HT Fast Real-Time PCR System and data were
collected using the Sequence Detection System 2.4 (SDS) software (Applied
Biosystems). To measure miRNA expression, we used miRNA TaqMan probes,
considered to be the gold standard for miRNA quantiﬁcation5. Expression was
calculated using the absolute quantitation standard curve method. RNU6B was
used as an endogenous control as it showed expression levels that remained
relatively constant with low variance and high abundance across the samples
tested. All primers used are described in Supplementary Table 15. All numerical
data are expressed as the mean±s.e.m. Statistical differences among groups were
analysed by Student’s t-test. Statistical signiﬁcance was calculated using
GraphPad Prism5 and SPSS 20. Po0.05 was considered statistically signiﬁcant.
For messenger RNA quantiﬁcation, total RNA was reverse transcribed using
MMLV reverse transcriptase (Gibco) and oligo(dT)16 primers (Invitrogen).
Real-time PCR reactions were run in triplicate using the ABI QuantStudio 6 Flex
Real-Time PCR System and data were collected using the QuantStudio Real-
Time PCR software (Applied Biosystems). Expression levels were calculated
using the relative quantiﬁcation method. Both b-actin and GAPDH were used as
endogenous controls. All primers can be found in Supplementary Table 15.
Gene expression data have been deposited in the Gene Expression Omnibus
(GEO) database under the accession code GSE97154 (https://www.ncbi.nlm.
nih.gov/geo/query/acc.cgi?acc=GSE97154).
Animal experiments. Male 10-week-old C57BL/6J mice, and 6-month-old CD1
retired breeders, were maintained on a 12 h light–dark cycle (lights on at 0700 h) at
22–25 C with ad libitum access to food and water. C57 mice were housed 5 per
cage except following defeat experiments at which point mice were singly housed.
All behavioural testing occurred during the animals’ light cycle. The experimenter
was blinded to the experimental group and the order of testing was counter-
balanced during behavioural experiments. All experiments were conducted in
accordance with the guidelines of the Institutional Animal Care and Use Com-
mittee at Icahn School of Medicine at Mount Sinai.
C57BL/6J mice were subjected to CSDS for 10 consecutive days, as described
previously49,50. Brieﬂy, C57BL/6J mice were subjected to 10 daily, 5min defeats by
a novel CD1 aggressor mouse and were then housed across a plexiglass divider to
allow for sensory contact. Control mice were housed in cages separated from other
control mice by a plexiglass divider and were rotated to a different cage daily.
Resilient and susceptible mice were identiﬁed by their respective preference for, or
avoidance of, interaction with a novel mouse after 10 days of defeat in a social
interaction test. Only control and susceptible mice were used for further study with
imipramine.
Social-avoidance behaviour was assessed with a novel CD1 mouse in a two-
stage social-interaction test. In the ﬁrst 2.5min test (no target), the experimental
mouse was allowed to freely explore an arena (44 44 cm) containing a plexiglass
and wire mesh enclosure (10 6 cm) against one wall of the arena. In the second
2.5min test (target), the experimental mouse was returned to the arena with a
novel CD1 mouse enclosed in the plexiglass wire mesh cage. Time spent in the
‘interaction zone’ (14 26 cm) surrounding the plexiglass wire mesh cage, ‘corner
zones’ (10 10 cm) and ‘distance travelled’ within the arena was measured by
video tracking software (Ethovision 5.0, Noldus).
Sucrose preference was assessed using a 2% sucrose solution or tap water in
50ml tubes with stoppers ﬁtted with ball-point sipper tubes. All animals were
acclimatized to two-bottle choice conditions before testing conditions. Daily, at
B1600 h, ﬂuid levels were noted, and tube positions were interchanged. Sucrose
preference was calculated as a percentage (100 volume of sucrose consumed/
total volume consumed (sucrose and water)) and was averaged over 2 days of
testing.
Susceptible mice were randomly assigned to treatment with either imipramine
(20mg per kg, daily) or a saline control (daily) treatment for 14 days. Blood was
collected from all animals via the saphenous vein before treatment. Rapid sampling
from the saphenous vein was used because it causes minimal discomfort or stress to
the animal. The blood was stored in RNAlater at  70 C until use. After treatment
and the second round of behaviour testing, animals were killed and blood was
collected via truncation into RNAlater and frozen at  70 C until use.
Then, 100 ng of total RNA was used to quantify expression levels of miRNAs
from animal blood samples using a probe-based miRNA expression assay
(NanoString Technologies, USA). Brieﬂy, hybridization of speciﬁc tags to target
miRNAs was annealed to create multiplex probe libraries from all samples. Each
miRNA of interest is identiﬁed by a ‘colour code’ generated by six ordered
ﬂuorescent spots present on a reporter probe and read by the nCounter Prep
Station Digital Analyzer. Control RNA was included to monitor ligation efﬁciency
and speciﬁcity throughout each step of the reactions. In addition, this protocol does
not include any ampliﬁcation steps that might introduce bias to the results. Raw
data were imported into NSolver Analysis Software v2.0 (NanoString technologies)
and normalized to the average counts to all endogenous genes. Data were further
normalized using internal positive spike-in controls to account for variability in the
hybridization process. Normalized data were imported into MultiExperiment
Viewer (MeV) software v.4.9 for further analysis. All numerical data are expressed
as the mean±s.e.m. Statistical differences among groups were analysed by
Student’s t-test. Po0.05 was considered statistically signiﬁcant.
Cell culture. For miRNA Overexpression experiments, human embryonic kidney
cells (HEK293) were cultured in Dulbecco’s modiﬁed Eagle’s medium supple-
mented with 10% fetal bovine serum, 100Uml 1 penicillin and 100 mgml 1
streptomycin (Invitrogen) in a 5% CO2 humidiﬁed incubator at 37 C. For miRNA
mimic treatments, cells were grown in the continuous presence of 5 nM miRNA
Mimic (miR-146a-5p, miR-146b-5p, miR-24-3p or miR-425-3p), 5 nM miR-Mimic
scramble control (AllStars Negative Control siRNA, Qiagen) or mock vehicle
(HiPerFect Transfection Reagent, Qiagen) for 24 h after which cell pellets were
collected and both mRNA and miRNA were extracted as previously explained. All
experiments were performed in triplicate. All numerical data are expressed as the
mean±s.e.m. Statistical differences among groups were analysed by one-way
analysis of variance with post hoc correction and Pearson’s correlation coefﬁcients.
Statistical signiﬁcance was calculated using GraphPad Prism5 and SPSS 20. Po0.05
was considered statistically signiﬁcant.
Human NPCs were treated as previously explained12. To ﬁnd adequate
antidepressant concentrations for treatment, cells were screened for cytotoxic
effects by measuring the activity of mitochondrial dehydrogenase using the
3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay
(Sigma-Aldrich Co) and antidepressants were applied at concentrations that
showed no toxicity in the MTT test. For chronic antidepressant treatment, cells
were grown in the continuous presence of 10 mM duloxetine, or no-drug control for
15 days, after which cell pellets were collected and both mRNA and miRNA were
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extracted. All experiments were performed in triplicate. All numerical data are
expressed as the mean±s.e.m. Statistical differences among groups were analysed
by independent Student’s t-tests. Statistical signiﬁcance was calculated using
GraphPad Prism5 and SPSS 20. Po0.05 was considered statistically signiﬁcant.
Data availability. Gene expression data have been deposited in the GEO database
under the accession code GSE97154. All other data that support the ﬁndings of this
study are available from the corresponding author on reasonable request (https://
www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE97154).
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